Publikation

The advent of biosimilars: challenges and risks

Wissenschaftlicher Artikel/Review - 01.07.2014

Bereiche
PubMed
DOI

Zitation
Müller R, Renner C, Gabay C, Cassata G, Lohri A, Hasler P. The advent of biosimilars: challenges and risks. Swiss Med Wkly 2014; 144:w13980.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Swiss Med Wkly 2014; 144
Veröffentlichungsdatum
01.07.2014
eISSN (Online)
1424-3997
Seiten
w13980
Kurzbeschreibung/Zielsetzung

Biosimilars represent a new class of medicinal products that will have significant impact on clinical use. They are identical on an amino acid sequence level to existing reference biopharmaceutical products (originals). However, they may exhibit differences on a protein level. This paper provides a brief overview of biosimilar development and describes the risk and challenges that should be considered during the admission of biosimilars into the clinic.